• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunity . Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations

tetano

Editor, Senior Moderator
Immunity


. 2021 Jul 29;S1074-7613(21)00294-6.
doi: 10.1016/j.immuni.2021.07.008. Online ahead of print.
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations


Frauke Muecksch[SUP] 1 [/SUP], Yiska Weisblum[SUP] 1 [/SUP], Christopher O Barnes[SUP] 2 [/SUP], Fabian Schmidt[SUP] 1 [/SUP], Dennis Schaefer-Babajew[SUP] 3 [/SUP], Zijun Wang[SUP] 3 [/SUP], Julio C C Lorenzi[SUP] 3 [/SUP], Andrew I Flyak[SUP] 2 [/SUP], Andrew T DeLaitsch[SUP] 2 [/SUP], Kathryn E Huey-Tubman[SUP] 2 [/SUP], Shurong Hou[SUP] 4 [/SUP], Celia A Schiffer[SUP] 4 [/SUP], Christian Gaebler[SUP] 3 [/SUP], Justin Da Silva[SUP] 1 [/SUP], Daniel Poston[SUP] 1 [/SUP], Shlomo Finkin[SUP] 3 [/SUP], Alice Cho[SUP] 3 [/SUP], Melissa Cipolla[SUP] 3 [/SUP], Thiago Y Oliveira[SUP] 3 [/SUP], Katrina G Millard[SUP] 3 [/SUP], Victor Ramos[SUP] 3 [/SUP], Anna Gazumyan[SUP] 3 [/SUP], Magdalena Rutkowska[SUP] 1 [/SUP], Marina Caskey[SUP] 3 [/SUP], Michel C Nussenzweig[SUP] 5 [/SUP], Pamela J Bjorkman[SUP] 6 [/SUP], Theodora Hatziioannou[SUP] 7 [/SUP], Paul D Bieniasz[SUP] 8 [/SUP]



Affiliations

Abstract

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) Spike receptor-binding domain (RBD)-specific antibodies from 5 individuals shortly after infection and later in convalescence to determine the impact of maturation over months. In addition to increased affinity and neutralization potency, antibody evolution changed the mutational pathways for the acquisition of viral resistance and restricted neutralization escape options. For some antibodies, maturation imposed a requirement for multiple substitutions to enable escape. For certain antibodies, affinity maturation enabled the neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.

Keywords: SARS-CoV-2; antibodies; neutralization.
 
Back
Top Bottom